Neuraminidase Constructs and production of synthetic RNA transcripts
Complete sequences for the human influenza A pandemic 2009 (H1N1) neuraminidase gene (segment 6), containing either the wild type (WT: p.H275) or the oseltamivir drugresistant SNP mutation (SNP: p.H275Y), were downloaded and aligned as described for the assay design to obtain a consensus for the WT and SNP sequences prevalent in the UK.
Synthetic flanking regions, containing promoter sequences, were designed to adjoin the 5' and 3' UTRs of the complete neuraminidase sequence to allow full in vitro transcription of segment 6 ( Figure S1A ).
Using overlapping synthetic oligonucleotides, each neuraminidase sequence along with the flanking sequences were cloned into the pEX-K plasmid with sequence validation performed by double strand Sanger sequencing (Eurofins) ( Figure S1B ). Four micrograms of each neuraminidase construct were linearised separately with KpnI (NEB) for 2 hours at 37 °C followed by purification using the QIAquick PCR purification kit (QIAGEN) with elution into 50 µl elution buffer. Linearisation was assessed using the 2100 Bioanalyzer with DNA 7500 series II kit (Agilent) ( Figure S1C ) and the concentration was estimated by using the Qubit® 2.0 fluorometer with the dsDNA HS Assay Kit (Invitrogen).
To generate biologically relevant negative strand RNA mimicking that found in vivo, in vitro transcription (IVT) was performed using the MEGAscript® T7 kit with incubation at 37 °C for two hours followed by TURBO DNase treatment (both from Life Technologies). Each reaction was purified using the RNeasy Mini Kit for RNA (QIAGEN) with elution into 50 µl RNase-free water. Transcribed RNA was assessed using the 2100 Bioanalyzer with RNA 6000 Nano kit (Agilent) ( Figure S1D ) and the concentration was estimated by using the Qubit® 2.0 fluorometer with the RNA HS Assay Kit (Invitrogen). To reduce freeze-thaw effects, IVTs were diluted to approximately 1 x 10 9 copies/µl in carrier and stored in single use aliquots at -80 °C. Carrier was commercially available RNA extracted from human lung cells (Life Technologies) at a final concentration of 15 ng/μl in 1 X TE. Duplex reactions containing both probes resulted in each partition having both a WT and SNP signal thereby enabling two dimensional (2D) scatter plots to be generated ( Figure S2C ).
Optimisation of H275Y assay
In mixed samples (containing both WT and SNP molecules) a fourth population of partitions was observed: the double occupancy partitions containing both molecules. The equivalent mixed sample 1D scatter plots were more difficult to resolve due to the mismatched amplified partitions ( Figure S2D ). Probe mismatch was observed as a 'lifting' or 'leaning' of the fluorescence amplitude in the WT or SNP only partitions, respectively in the 2D plots ( Figure   S2C ), but were observed as a merging of the double occupancy and mismatch populations in the 1D plots ( Figure S2D ).
The effect of the annealing temperature (T A ) on the quantification was investigated E Materials and methods; Supplemental material (Section 5) Cq or raw data submission using RDML D *: Assessing the absence of DNA using a no RT assay is essential when first extracting RNA. Once the sample has been validated as DNA-free, inclusion of a no-RT control is desirable, but no longer essential. **: Disclosure of the probe sequence is highly desirable and strongly encouraged. However, since not all commercial pre-designed assay vendors provide this information, it cannot be an essential requirement. Use of such assays is advised against. 
Evaluation of the sensitivity of dPCR

Defining the detection capability of dPCR
For the analysis of the WT only samples, the detection capability was calculated from the log transformed λ and % SNP data using the R statistical programming environment. A standard analytical chemistry method based on the dispersion of samples containing only WT was employed to compute the detection limits (2) . Briefly, the principle is as follows:
i. An upper limit on the background (false positive rate) level is determined, that is, the maximum response or concentration which is likely to be produced by a sample containing no analyte. This is referred to as the decision limit, and a common definition is the level L at which there is a probability of 0.05 that a blank sample will give a result at or above L (α = 0.05, the Type I error rate) ( Figure S4A) .
ii. The variability of the response is determined, and a second level determined which is above the decision limit by a number of standard deviations dependent on the distribution and specific requirements. This is the detection capability, and it is the concentration at which a sample which does contain analyte is unlikely to produce a result which lies below the decision limit. In other words, the detection capability is the level above which the result is unlikely to be consistent with and mistaken for a negative sample. For example, for a Normal distribution, a detection capability which is 1.645 standard deviations above decision limit corresponds to a limit which has only a 0.05 probability of a result below the decision limit (so β = 0.05, the Type II error rate) ( Figure S4A ).
For the analysis, the relevant response variables were the mean number of copies per partition (λ) and the % SNP in the sample. The data was transformed by taking the natural log (ln) of λ and % SNP as described previously (3). A linear relationship between log λ and log % SNP was identified for each RNA concentration which had an approximate Normal distribution and constant variance ( Figure S4B) . The [high] sample showed a greater variation than [low] and [medium] samples which were similar. The distributions were highly non-Normal, being bounded at zero and somewhat asymmetric. Therefore, the decision limits were calculated using two approaches: using the maximum observed value, and an estimate based on Chebyshev's inequality (4) . Briefly, the Chebyshev method uses the fact that in a nonsymmetrical arbitrary distribution of data, a proportion (p) lies within k standard deviations above the mean:
This was be rearranged to find the appropriate value of k for, for example, p = 0.95. Of the two methods the Chebyshev is more conservative (resulted in the higher decision limit) since it is distribution free and the number of standard deviations from the mean is quite large for a coverage of 95% (4). Conversely, using the maximum observed value has a disadvantage in that it depends on the data set for a specific set of results that cannot be assumed to be a reproducible estimate of the upper 95% limit of the distribution. Therefore, comparing these two method gives an indication of the likely range for the detection capability. The resulting decision limits were calculated ( Table 1 ) and an observed λ above the decision limit was considered to be inconsistent with a sample containing no SNP molecules.
The decision limit and residual standard error estimates were used to calculate detection capability on the log (λ) as follows:
where s is the residual standard error from the linear regression. The linear model ( Figure   S4B ) was used to project the decision limit onto the log % SNP scale and the corresponding % SNP was calculated and defined as the then the detection capability ( Table 1 ). Figure S4 . Defining the detection capability of dPCR for rare SNP detection by dPCR. (A) Schematic showing the relationship between the decision limit (blue) and detection capability (red). The detection capability is the level above which the result is unlikely to be consistent with and mistaken for a negative sample with 95% confidence. (B) Scatter plot illustrating the linear relationship between ln λ and ln % SNP for the three sample concentrations.
One-step reverse transcription quantitative PCR
For analysis of the clinical samples, a number of PCR based methods were used to evaluate the RNA: i. H1N1 typing using the FluA H1N1 assay to identify influenza A H1N1 in patients at UCLH.
ii. Identify the presence of mutant (SNP) sequences using the UCLH_RT-qPCR assay to screen for oseltamivir resistance using a one-step RT-qPCR method at UCLH.
iii. Quantify the concentration of WT and SNP sequences using the LGC_RT-qPCR and
LGC_dPCR.
i. H1N1 typing (UCLH)
For the H1N1 typing assay (FluA H1N1 assay), the Influenza A H1N1 swl forward and reverse primers were used with the Influenza A H1N1 swl Probe (Table S1) as described previously (1). Brome mosaic virus (BMV) was used as an internal control with primers BMV taq1&2 and BMV Probe as described previously (Table S1) To establish the dynamic range of the assay, SNP RNA sequence was generated from a synthesised (Eurofins MWG/Operon) oligonucleotide that spanned the entire primer/probe region and contained the SNP (5'-GGG AAA GAT AGT CAA ATC AGT CGA AAT GAA TGC CCC TAA TTA TTA CTA TGA GGA ATG CTC CTG TTA TCC TGA TT-3'). A standard curve generated by 10-fold dilutions of the SNP containing oligonucleotide from 1 in 10 12 copies per reaction were measured using the UCLH_RT-qPCR ( Figure S5A ).
Viral RNA extracted from serial dilutions of a cell culture propagating a pandemic H1N1
virus encoding the H275Y SNP (POS sample) was used to establish the analytical sensitivity of the method. To determine the copy number of this sample, one-step RT-qPCR was performed using the UCLH_RT-qPCR on 10-fold dilutions to end point to establish the lowest dilution to give a positive result and the highest dilution to give a negative result. Ten replicates of these two dilutions were further evaluated and the copy number in these dilutions was calculated by a Poisson distribution method (5) . Briefly, the copy number is equal to -ln [F] , where F is the fraction of negative reactions, assuming an RT efficiency of 100%. The copy number obtained was multiplied by the dilution factor to give the copy number of the original sample.
RNA from this sample was subsequently diluted to give extracts containing 500, 250, 100, 50, 25 and 10 RNA copies/mL. These dilutions were tested with 8 replicates each on three separate occasions to give a total of 24 replicates at each dilution. A 95% level of sensitivity of 223 copies/mL (4.95 copies/reaction) was calculated using Probit analysis (Arcus QuickStat Biomedical v1.0, Research Solutions. Cambridge. UK).
The UCLH_RT-qPCR was tested against pre-pandemic seasonal influenza A strains (H1N1 and H3N2), the avian influenza A strain H5N1, Influenza B and other common respiratory viruses (respiratory syncytial virus, parainfluenza viruses, human metapneumovirus, and adenovirus); none of these viruses were detected by the UCLH_H275Y assay demonstrating that the assay was specific to pandemic influenza A H1N1 virus only.
Assay specificity was performed using duplex reactions containing the WT and SNP probes. Mixed populations of wild type oseltamivir sensitive and resistant viruses were generated by varying ratios with a concentration of 1 x 10 5 viral copies/mL and tested with the assay (Figure S5B ). Neither SNP nor WT probes were detected when only 5% was present. i.e.
the SNP probe gave a signal when there was only 5% resistant virus and 95% wild type virus, and vice versa ( Figure S5B ). iii. One-step reverse-transcription quantitative PCR (LGC_RT-qPCR)
Briefly, 25 µl reactions were prepared containing 1 X reaction buffer, 1 X enzyme mix, H275Y assay (Table S1 ) and 7.5 µl RNA. RT-qPCR was performed using the Prism 7900HT Real Time PCR system (ABI). Control reactions were performed using carrier or water containing no template; in all cases no amplification occurred ( Figure S6A) . Standard curves were generated using an eight-point ten-fold dilution series of the RNA IVTs containing 7.5 x 10 7 to 7.5 copies/reaction ( Figure S6B) . RT was performed at 45 °C for 30 minutes with by enzyme inactivation at 95 °C for 15 minutes, followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 60 seconds.
The lowest concentration of SNP or WT RNA was 75 copies/reaction and was defined as the assay sensitivity. Mismatching occurred throughout the reaction with the mismatch RNA being amplified about 3.3 cycles behind the matched indicating that the specificity of this assay was approximately 90% (Figure S6C ). Using the standard curve, quantification of the mismatched template/assay with both uniplex and duplex assays defined the specificity as 90% and 87% for the WT and SNP probes ( Figure S6C ) relative to the matched template/assay quantification. For analysis of the clinical samples, the standard curve was used to convert the Cq value into copies/µl. Linear regression was applied and the R 2 and PCR efficiency (E% = (10(-1/slope) -1) x 100) computed. Confidence intervals were calculated using the Student's t-distribution (95% CI = mean ± T value x SD/√n). 
